In recent years, purpose-built commercial space for life sciences research and development (R&D) has been an outperforming alternative property type more frequently pursued by real estate investors. Clarion Partners believes life sciences industry clusters are creating more prosperous U.S. cities, while occupancy and rent growth trends have been robust for property owners.

A few powerful economic and demographic factors are driving a significant acceleration of capital investment into the life sciences sector.

- **An Aging Population.** Seniors account for a rising share of the U.S. population. The cohort now represents about 16% of Americans and has been forecasted to grow to over 20% by 2030 (Figure 1a). At the same time, average life expectancy increased from 72.6 years in 1975 to 78.9 years in 2019. On average, seniors spend over $19K per annum on healthcare (Figure 1b).

- **Rising Health Care Spending.** Over the next decade, national health care spending is projected to grow at an average rate of 5.5% per year and is likely to rise as a percentage of U.S. GDP to about 20% by 2028, up from about 18% in 2020 (Figure 1c).

- **The Coronavirus Epidemic.** The global COVID-19 pandemic will likely be a boost for life sciences funding and fuel new medical and drug treatments for commercialization. This follows three consecutive years of Food and Drug Administration (FDA) novel drug approvals from 2017 to 2019 well-above the long-term average (Figure 1d).

- **More Synergy between Health Care and Technology.** At the same time, there are more and more crossovers between health care and technology innovation. This synergy has spurred tremendous growth across the U.S., which has been hyper-concentrated in certain high-cost markets and is now spreading to new growth centers.

### DRUG APPROVALS AND HEALTH CARE SPENDING HIGH AMIDST GROWTH IN U.S. SENIOR POPULATION

**Figure 1a:** Senior Population Growth Forecast

**Figure 1b:** Per Capita Health Care Spending by Age Cohort

**Figure 1c:** Health Care Spending Forecast

**Figure 1d:** FDA Novel Drug Approvals

Source: Moody’s Analytics, Centers for Medicare and Medicaid Services, Clarion Partners Investment Research, Q2 2020. Note: Senior population growth and health care spending forecasts from Moody’s Analytics as of September 2020.
INVESTABLE UNIVERSE GROWING FAST ALONG WITH MORE CAPITAL FLOWS

The investable universe for life sciences real estate is estimated at $100 billion, which is growing rapidly (Figure 2).

Three major sources of capital are driving R&D in the life sciences sector and are all at a record high:
- Private life sciences venture capital (VC) funding;
- Public funding from National Health Institute (NIH); and,
- Corporate biopharma capital.

FIGURE 2: TOTAL U.S. LIFE SCIENCES R&D CAPITAL INVESTMENT BY SOURCE ($ BILLIONS)

Source: National Institute of Health, PitchBook, PhRMA, Clarion Partners Investment Research. Q3 2020

Over the past five years, sizeable socioeconomic tailwinds have driven average annual growth rates between 5% and 20% in each of these funding categories. R&D spending by corporations and large pharmaceutical companies is by far the biggest source of funding. Major companies like Johnson & Johnson, Roche, Pfizer, Novartis, and Merck are investing heavily in life-saving technologies and therapeutics. Annual life sciences R&D spending in biopharma is even comparable to that of big tech giants, such as Amazon, Alphabet, Microsoft, and Apple.6

LIFE SCIENCES CLUSTERS

Locational “clustering” is a dominant theme in life sciences. The clustering effect is due to the intrinsic benefits of the locational convergence of large hospitals, leading universities, research institutions, life sciences and biotechnology companies, highly educated work forces, and capital funding. The three most established and booming life sciences centers are Boston/ Cambridge, San Francisco, and San Diego, all of which have large inventories of highly-specialized purpose-built lab and R&D facilities.

Clarion Partners believes there are two tiers of target investment markets based on the count of highly specialized lab inventories:

Tier 1:
- Boston/Cambridge, Longwood Medical, Seaport and surrounding submarkets;
- SF/South San Francisco, Mission Bay, Mid-Peninsula, Emeryville/Berkley; and,
- San Diego/Torrey Pines, University Towne Center, and Sorrento Valley;

Tier 2:
- NYC/NJ
- Raleigh-Durham (Research Triangle);
- Seattle
- Maryland/DC
- Philadelphia

In top life sciences clusters, there is generally low new supply and strong demand for Class A inventory, which has led to low vacancy levels and strong rent growth. Occupiers are willing to pay high rents for the best locations and facilities. Tier 1 markets reported 5-year average effective office rent growth of 8.9%, well-above the U.S. office average of 3.0% (as of Q4 2019) (Figure 3).

FIGURE 3: TOP LIFE SCIENCES CLUSTERS: 5-YEAR AVERAGE EFFECTIVE OFFICE RENT GROWTH


This does not constitute investment advice. All information has been developed by Clarion Partners or obtained from sources that Clarion Partners believes to be reliable. This material is not an offer to sell or a solicitation of an offer to buy any security. Investment in real estate involves significant risk. Investors should consider their investment objectives and their risk tolerance before investing.
At the same time, these innovation nodes have proven to have significant ancillary benefits on local economies and communities. Different industries centered around these hubs have proven to be more productive overall. Innovation clusters have reported outsized median household income levels, wage growth, and home price appreciation. In fact, the Brookings Institute reports the regional divergence has reached extreme levels in areas where the U.S. innovation sector has thrived. It states:

“The innovation sector—comprised of 13 of the nation’s highest-tech and R&D “advanced” industries—contributes inordinately to regional and U.S. prosperity. Its diffusion into new places would greatly benefit the nation’s well-being. However, far from diffusing, the sector has been concentrating in a short list of superstar metropolitan areas. Most notably, just five top innovation metro areas—Boston, San Francisco, San Jose, Seattle, and San Diego—accounted for more than 90% of the nation’s innovation-sector growth during the years 2005 to 2017... increasing their share of the nation’s total innovation employment from 17.6% to 22.8% since 2005.”

In the years ahead, Clarion Partners believes there will likely be a greater dispersion into the aforementioned “Tier 2” markets, largely due to the high cost of business occupancy and living overall in top clusters.

PURPOSE-BUILT LAB FACILITIES

Typical purpose-built life sciences research lab facility requirements are highly specialized, driven by the handling, managing, and storage of chemicals and scientific equipment. The initial development costs for lab office are therefore generally higher than those of traditional office.

They often have features such as:
- High ceilings (optimally 15’-16’ slab to slab);
- Large open floor plates;
- High-powered base building HVAC systems;
- Individualized exhaust system & emergency generator power, and;
- Separate elevator shafts/ loading docks.

SIGNIFICANT INVESTMENT OUTPERFORMANCE

While the full effects of the COVID-19 pandemic on demand for office space, including life sciences office space, are uncertain, we believe it is an excellent time to concentrate on this segment with a rapidly expanding market size yet with few large institutional players.

More and more institutional investors are beginning to pursue life sciences real estate due to the strength of property-level fundamentals that are less correlated to the economic cycle risks due to the more inelastic demand from the health care industry. Overall, high-quality assets have demonstrated core-like investment characteristics, which include:
- Relatively stable cash flow;
- Lower measured risk;
- A large and growing investable market; and,
- A good track record of higher tenant retention rate (80%) / lower ongoing capital expenditure.

1 Moody’s Analytics. Q2 2020.
2 Centers for Medicare and Medicaid Services. 2020
3 Congressional Budget Office. Note: Forecast based on 2018-27.
8 Note: “Innovation industries” are a subset of advanced industries that include the 13 most STEM and R&D intensive industries.
DEFINITIONS

**Gross Domestic Product (GDP)** is an economic statistic which measures the market value of all final goods and services produced within a country in a given period of time.

A **global pandemic** is the worldwide spread of a new disease. The World Health Organization declared COVID-19 to be a pandemic when it became clear that the illness was severe and that it was spreading quickly over a wide area.

**COVID-19** is the World Health Organization’s official designation of the current novel coronavirus disease. The virus causing the novel coronavirus disease is known as SARS-CoV-2.

**Real Estate Investment Trusts (REITs)** invest in real estate or loans secured by real estate and issue shares in such investments, which can be illiquid.

**National Association of Real Estate Investment Trusts (NAREIT)** serves as the worldwide representative voice for REITs and real estate companies with an interest in U.S. real estate.

**Biopharma** is the study and development of the use of living things, especially cells and bacteria in the production of medicine and drugs.

**Therapeutic** is the healing of disease.

**A Heating, Ventilation, and Air Conditioning (HVAC) system** is responsible for heating and cooling a building. It’s also a source of proper ventilation, allowing for moisture to escape.
IMPORTANT INFORMATION

All investments involve risk, including possible loss of principal.

The value of investments and the income from them can go down as well as up and investors may not get back the amounts originally invested, and can be affected by changes in interest rates, in exchange rates, general market conditions, political, social and economic developments and other variable factors. Investment involves risks including but not limited to, possible delays in payments and loss of income or capital. Neither Franklin Resources, Inc. nor any of its affiliates guarantees any rate of return or the return of capital invested.

Equity securities are subject to price fluctuation and possible loss of principal. Fixed-income securities involve interest rate, credit, inflation and reinvestment risks; and possible loss of principal. As interest rates rise, the value of fixed income securities falls.

International investments are subject to special risks including currency fluctuations, social, economic and political uncertainties, which could increase volatility. These risks are magnified in emerging markets.

Commodities and currencies contain heightened risk that include market, political, regulatory, and natural conditions and may not be suitable for all investors.

Past performance is no guarantee of future results. Please note that an investor cannot invest directly in an index. Unmanaged index returns do not reflect any fees, expenses or sales charges.

The opinions and views expressed herein are not intended to be relied upon as a prediction or forecast of actual future events or performance, guarantee of future results, recommendations or advice. Statements made in this material are not intended as buy or sell recommendations of any securities. Forward-looking statements are subject to uncertainties that could cause actual developments and results to differ materially from the expectations expressed. This information has been prepared from sources believed reliable but the accuracy and completeness of the information cannot be guaranteed. Information and opinions expressed by either Franklin Resources, Inc. or its affiliates are current as at the date indicated, are subject to change without notice, and do not take into account the particular investment objectives, financial situation or needs of individual investors.

The information in this material is confidential and proprietary and may not be used other than by the intended user. Neither Franklin Resources, Inc. or its affiliates or any of its officer or employee of Franklin Resources, Inc. accepts any liability whatsoever for any loss arising from any use of this material or its contents. This material may not be reproduced, distributed or published without prior written permission from Franklin Resources, Inc. Distribution of this material may be restricted in certain jurisdictions. Any persons coming into possession of this material should seek advice for details of, and observe such restrictions (if any).

This material may have been prepared by an advisor or entity affiliated with an entity mentioned below through common control and ownership by Franklin Resources, Inc. Unless otherwise noted the “$” (dollar sign) represents U.S. Dollars.
This material is only for distribution in those countries and to those recipients listed.

All investors and eligible counterparties in EU and EEA countries:
In Europe (excluding UK and Switzerland), this financial promotion is issued by Legg Mason Investments (Ireland) Limited, registered office Floor 6, Building Three, Number One, Ballsbridge, 126 Pembroke Road, Ballsbridge, Dublin 4. D04 EP27, Ireland. Registered in Ireland, Company No. 271887. Authorised and regulated by the Central Bank of Ireland.

In the UK, this financial promotion is issued by Legg Mason Investments (Europe) Limited, registered office 201 Bishopsgate, London EC2M 3AB. Registered in England and Wales, Company No. 1732037. Authorized and regulated by the UK Financial Conduct Authority.

In Switzerland, this financial promotion is issued by Legg Mason Investments (Switzerland) GmbH.

Investors in Switzerland: The representative in Switzerland is FIRST INDEPENDENT FUND SERVICES LTD., Klausstrasse 33, 8008 Zurich, Switzerland and the paying agent in Switzerland is NPB Neue Privat Bank AG, Limmatquai 1, 8024 Zurich, Switzerland. Copies of the Articles of Association, the Prospectus, the Key Investor Information documents and the annual and semi-annual reports of the Company may be obtained free of charge from the representative in Switzerland.

All Investors in Hong Kong and Singapore:
This material is provided by Legg Mason Asset Management Hong Kong Limited in Hong Kong and Legg Mason Asset Management Singapore Pte. Limited (Registration Number (UEN): 200007942R) in Singapore.

This material has not been reviewed by any regulatory authority in Hong Kong or Singapore.

All Investors in the People’s Republic of China (“PRC”):
This material is provided by Legg Mason Asset Management Hong Kong Limited to intended recipients in the PRC. The content of this document is only for Press or the PRC investors investing in the QDII Product offered by PRC’s commercial bank in accordance with the regulation of China Banking Regulatory Commission. Investors should read the offering document prior to any subscription. Please seek advice from PRC’s commercial banks and/or other professional advisors, if necessary. Please note that Legg Mason and its affiliates are the Managers of the offshore funds invested by QDII Products only. Legg Mason and its affiliates are not authorized by any regulatory authority to conduct business or investment activities in China.

This material has not been reviewed by any regulatory authority in the PRC.

Distributors and existing investors in Korea and Distributors in Taiwan:
This material is provided by Legg Mason Asset Management Hong Kong Limited to eligible recipients in Korea and by Legg Mason Investments (Taiwan) Limited (Registration Number: (109) Jin Guan Tou Gu Xin Zi Di 016; Address: Suite E, 55F, Taipei 101 Tower, 7, Xin Yi Road, Section 5, Taipei 110, Taiwan, R.O.C.; Tel: (886) 2-8722 1666) in Taiwan. Legg Mason Investments (Taiwan) Limited operates and manages its business independently.

This material has not been reviewed by any regulatory authority in Korea or Taiwan.

All Investors in the Americas:
This material is provided by Legg Mason Investor Services LLC, a U.S. registered Broker-Dealer, which includes Legg Mason Americas International. Legg Mason Investor Services, LLC, Member FINRA/SIPC, and all entities mentioned are subsidiaries of Legg Mason, Inc.

All Investors in Australia and New Zealand:
This document is issued by Legg Mason Asset Management Australia Limited (ABN 76 004 835 839, AFSL 204827). The information in this document is of a general nature only and is not intended to be, and is not, a complete or definitive statement of matters described in it. It has not been prepared to take into account the investment objectives, financial objectives or particular needs of any particular person.

The aforementioned Legg Mason entities are wholly owned subsidiaries of Franklin Resources, Inc.

©2020, Franklin Resources, Inc. All rights reserved.